Levobupivacaïne Fresenius Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This stabilises the neuronal membrane, halting nerve impulse transmission and resulting in reversible loss of sensation in the area where the drug is applied.

The specific dose of levobupivacaine is determined by the prescribing clinician based on the procedure, patient characteristics, and route of administration. Healthcare professionals calculate the appropriate concentration and volume to achieve effective anesthesia while minimizing toxicity.

Safety data for levobupivacaine in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the obstetrician or anesthesiologist. Breastfeeding mothers should consult their physician before exposure.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine, offering a similar duration of action with a lower risk of cardiotoxicity and central nervous system toxicity. Clinicians often prefer levobupivacaine when a safer safety margin is desired, especially for high‑dose or continuous infusions.

Store the product below 25 °C in its original packaging, protected from moisture and direct sunlight. Ensure the container is tightly sealed to prevent contamination. Follow standard aseptic handling procedures when preparing for injection.

Levobupivacaine is administered by a qualified healthcare professional via epidural, infiltration, intrathecal, or peripheral nerve block techniques. The drug is injected directly into the target tissue or space after confirming correct needle placement and aspiration to avoid intravascular delivery.

The most serious risks include systemic toxicity manifesting as seizures, cardiac arrhythmias, or respiratory depression, as well as severe allergic reactions. Prompt recognition of early signs such as tinnitus, metallic taste, or circumoral numbness is essential, and immediate supportive measures should be taken.

Levobupivacaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals receiving other potent local anesthetics that could lead to additive toxicity. Contra‑indications are determined by the treating physician.